Creating a Patent Clearinghouse in Canada: A Solution to Problems of Equity and Access
Bibliographic record
Abstract
Two of the most pressing normative questions surrounding biotechnology patenting today relate to the equitable distribution of the products of biotechnological research and ensuring fair access to those products. Often discussed under the heading sharing, the problem of the equitable distribution of biotechnology's advances is a mixture of two normative concerns: whether there is a universal right to benefit from scientific progress and whether particular research subjects have a right to share in the benefits of research using their tissues. The question of access is similarly twofold. On one hand, researchers are concerned that patent rights may block second generation innovation by placing licensing and monetary roadblocks in the way of research. This is the so-called problems that has been discussed theoretically but has yet to be demonstrated or disproved empirically. The second aspect of this question is patient access to new technologies, such as new screening tests or potential treatments based on the use of stem-cells. This poster focuses on a few legal mechanisms that may facilitate both access to biotechnology's products and the equitable distribution of the benefits arising from those products. In particular, we suggest the creation of an independent and non-profit patent clearinghouse. This clearinghouse would administer patents in a particular field of study (e.g., all stem cell related patents) and would distribute income to patent holders arising from that administration. Specifically, the clearinghouse would charge a fixed fee for use of patent rights that would be distributed to patent owners. At the same time, the clearinghouse would hold back a certain percentage of profits (the HUGO Ethics Committee recommends, for example, between 1 and 3%) for redistribution to health care infrastructure in low-income countries. The clearinghouse would ensure that all researchers have fair access to innovations in the field while ensuring a fair economic return to patentees. What is a Patent? A patent is a government grant of a time-limited legal monopoly given to an inventor in exchange for the public disclosure of an invention. It can be thought of as a veto over the activities of others in respect of making, using, selling or importing an invention. It permits the inventor or an assignee (often a corporation) to commercially exploit the invention. What are the Criteria for Patentability in Canada? An invention, to be patentable, must be new, useful and non-obvious. These are legal terms that have been defined in Canadian case law as follows: New--the invention must not have been previously disclosed in a single source more than 12 months prior to the filing of the patent application. Useful--the invention must work and must be of industrial interest. Non-obvious--To be patentable, an invention must be a development or an improvement that would not have been obvious beforehand to persons skilled in the art. The Current International Trend To mitigate the anticommons effect that patents have on access to novel biotechnological applications, mechanisms to promote and to facilitate access to medicine have been suggested by the Human Genome Organization, The United Nations and the World Trade Organization. Human Genome Organization Ethics Committee, Statement on Benefit Sharing 1. In the interest of justice, there is an evolving international consensus that suggests that groups participating in genetic research should receive some benefit. 2. Permissible benefit-sharing mechanisms may include: agreements with individuals, families, groups, communities or populations that foresee technology transfer, local training, joint ventures, provision of health care or of information infrastructures, reimbursement of costs, or the possible use of a percentage of any royalties for humanitarian purposes. …
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.009 | 0.029 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.005 | 0.005 |
| Science and technology studies | 0.019 | 0.007 |
| Scholarly communication | 0.015 | 0.010 |
| Open science | 0.004 | 0.007 |
| Research integrity | 0.010 | 0.007 |
| Insufficient payload (model declined to judge) | 0.017 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".